Adverse Events of Monoclonal Antibodies Used for Cancer Therapy

Table 1

Monoclonal antibodies (MoAbs) approved for cancer therapy.

MoAb	Trade name	Target	Type	Indication(s)
Cetuximab	Erbitux	EGFR	Chimeric IgG1κ	HNC and colorectal cancer
Panitumomab	Vectibix	EGFR	Human IgG2κ	Colorectal carcinoma
Nimotuzumab	Nimotuzumab	EGFR	Human IgGh-R3	HNC
Bevacizumab	Avastin	VEGFR	Humanized IgG1κ	Colorectal, renal, lung, and brain cancer
Ramucirumab	Cyramza	VEGFR	Humanized IgG1κ	Gastric or gastresophageal junction cancer
Trastuzumab	Herceptin	HER2	Humanized IgG1κ	Breast cancer,; gastric or gastroesophageal junction cancer
Trastuzumabemtansine	Kadcyla	HER2	Humanized IgG1κ	Breast cancer
Pertuzumab	Perjeta	HER2	Humanized IgG1κ	Breast cancer
Alemtuzumab	Campath	CD52	Humanized IgG1κ	Chronic lymphocytic leukemia
Rituximab	Rituxan; MabThera	CD20	Chimeric IgG1κ	Chronic lymphocytic leukemia and non-Hodgkin lymphoma
Ofatumumab	Arzerra	CD20	Human IgG1κ	Chronic lymphocytic leukemia
Obinutuzumab	Gazyva	CD20	Human IgG1	CLL
Ibritumomab	Zevalin	CD20	Murine IgG1κ	Non-Hodgkin lymphoma
Tositumomab	Bexxar	CD20	Murine IgG2aλ	Non-Hodgkin lymphoma
Brentuximab Vedotin	Adcetris	CD30	Chimeric IgG1κ	Hodgkin’s and anaplastic large cell lymphoma
Ipilimumab	Yervoy	CTLA-4	Human IgG1κ	Melanoma
Catumaxomab	Removab	EpCAM	Rat IgG2b/mouse; IgG2a bispecific	Malignant ascites in patients with ePCaM + cancer
Denosumab	Prolia; Xgeva	RANKL	Human IgG2κ	Breast cancer, prostate cancer, and giant cell tumors of the bone
Nivolumab	Opdivo	PD-1	Human IgG4	Melanoma
Siltuximab	Sylvant	IL-6	Chimeric IgG1κ	Castleman disease, multicentric (in patients who are HIV negative and HHV-8 negative)